Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.

Yasuo TerauchiDaisuke YabeHideaki KanetoAtsushi AmanoMike BaxterDaisuke WatanabeHirotaka WatadaNobuya Inagaki

Published in: Diabetes, obesity & metabolism (2021)

iGlarLixi was consistently effective across all baseline characteristic subgroups, with more patients achieving glycaemic control vs iGlar early in treatment.

Keyphrases

type diabetes
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
glycemic control
randomized controlled trial
clinical trial
insulin resistance
smoking cessation